MAPT and Alzheimer disease: Finally, we aimed to explore an immunoassay-based staging of AD, but unfortunately, while p-tau217 and NTA-tau could be measured in CSF and blood using the same analytical platform, this was not possible for plasma p-tau205, because the only available method was IP-MS.